Maxim Group analyst Jason McCarthy maintained a Buy rating on Synthetic Biologics (SYN – Research Report) yesterday and set a price target of $1.00. The company's shares closed last Tuesday at $0.22, close to its 52-week low of $0.20. According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -39.1% and a 10.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group. Currently, the analyst consensus on Synthetic Biologics is a Moderate Buy with an average price target of $1.63.
https://www.tipranks.com/news/blurbs/maxim-group-thinks-synthetic-biologics-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Synthetic Biologics (AMEX:SYN)
Graphique Historique de l'Action
De Mar 2023 à Mar 2023 Plus de graphiques de la Bourse Synthetic Biologics
Synthetic Biologics (AMEX:SYN)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023 Plus de graphiques de la Bourse Synthetic Biologics